Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine-carboplatin plus necitumumab in first-line treatment of squamous NSCLC
2016-002041-31Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of necitumumab in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Primary endpoint: Objective response rate (ORR). Started Sep 2016; status: completed.
02
Drugs
necitumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-002041-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002041-31.